NCT02238145 - Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease | Crick | Crick

Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease

N/ACompletedNCT02238145

Boehringer Ingelheim660 enrolled

Overview

To obtain further information on the tolerability and efficacy of Atrovent® inhaletten® in the treatment of chronic obstructive airways disease under conditions of daily practice

Study Type

OBSERVATIONAL

Enrollment

660

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Atrovent® InhalettenDRUG

Eligibility

Sex: ALLMin age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Primarily patients of both gender, older than 30 years,who suffer from chronic obstructive airways disease * Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion Exclusion Criteria: \- Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® Inhaletten®

Outcomes

Primary Outcomes

Investigator assessment of improvement in the clinical picture of the course on a 6-point symptoms profile

Time frame: Up to 4 weeks after first study drug administration

Secondary Outcomes

Investigator assessment of tolerability on a 4-point scale

Time frame: Up to 4 weeks after first study drug administration

Investigator assessment of efficacy on a 4-point scale

Time frame: Up to 4 weeks after first study drug administration

Number of patients with adverse drug reactions

Time frame: Up to 4 weeks after first study drug administration

Number of patients who withdrew from the study

Time frame: Up to 4 weeks after first study drug administration

Number of patients who changed the concomitant medication

Time frame: Up to 4 weeks after first study drug administration

Number of patients who continued treatment

Time frame: Up to 4 weeks after first study drug administration

Patient assessment of tolerability on a 4-point scale

Time frame: Up to 4 weeks after first study drug administration

Patient assessment of efficacy on a 4-point scale

Time frame: Up to 4 weeks after first study drug administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.